search
Back to results

Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects

Primary Purpose

Healthy Subjects, Overactive Bladder

Status
Completed
Phase
Phase 1
Locations
Study Type
Interventional
Intervention
Formulation 1 solabegron
Formulation 2 solabegron
Sponsored by
Velicept Therapeutics, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Healthy Subjects, Overactive Bladder focused on measuring Overactive bladder, Incontinence

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Body weight greater than or equal to 50 kg, inclusive, and body mass index (BMI) 18.0 - 32.0 kg/m2, inclusive
  • In good general health as determined by a thorough medical history and physical examination, ECG, vital signs, and clinical laboratory evaluation. Results of clinical laboratory tests must be without clinically significant abnormalities, including hematology, clinical chemistry and urinalysis.
  • Adequate venous access to allow for repeated blood sampling
  • Ability to understand and comply with the study requirements
  • Provide written informed consent prior to any study procedure being performed (all subjects should be able to understand the informed consent form and any other documents that subjects are required to read).

Exclusion Criteria:

  • Any clinically relevant abnormality identified on the screening physical examination, clinical laboratory tests, 12-lead ECG, or any other medical condition or circumstance which would make the subject unsuitable for participation in the study based on the Investigator's assessment
  • Resting heart rate greater than or equal to 100 beats per minute (BPM) after 5 minutes rest (as above) at the screening visit
  • QTcF interval (Fredericia's correction factor) greater than 450 msec (males subjects) at screening
  • History of drug or other allergy, which, in the opinion of the Investigator, contraindicates their participation
  • History of smoking, including e-cigarettes, within 3 months of the study and/or a positive urine cotinine at screening
  • Regular alcohol consumption averaging ≥ 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of the first dose of study medication.
  • Positive urine drug or alcohol test at screening
  • Any other condition and/or situation that causes the Investigator to deem a subject unsuitable for the study (e.g., due to expected study medication non-compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures)

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Experimental

    Arm Label

    Formulation 1 solabegron

    Formulation 2 solabegron

    Arm Description

    Subjects will receive formulation 1 solabegron doses in a single-blind, randomized, cross-over fashion in Periods 1 to 3.

    Subjects will receive formulation 2 in a single-blind, randomized, cross-over fashion in Periods 1 to 3.

    Outcomes

    Primary Outcome Measures

    Maximum observed plasma drug concentration (Cmax)

    Secondary Outcome Measures

    Full Information

    First Posted
    October 12, 2016
    Last Updated
    April 23, 2019
    Sponsor
    Velicept Therapeutics, Inc.
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02938507
    Brief Title
    Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects
    Official Title
    A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Immediate and Modified Release Formulations of Orally Administered Solabegron in Healthy Male Subjects
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2019
    Overall Recruitment Status
    Completed
    Study Start Date
    October 2016 (undefined)
    Primary Completion Date
    December 2016 (Actual)
    Study Completion Date
    December 2016 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Velicept Therapeutics, Inc.

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of different formulations of orally administered solabegron in healthy male subjects.
    Detailed Description
    The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of different formulations of orally administered solabegron in healthy male subjects. Eligible male subjects will be enrolled into 2 cohorts of 12 subjects each conducted in parallel. The study is a single blind (subjects), randomized, cross-over design in 3 study periods.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Healthy Subjects, Overactive Bladder
    Keywords
    Overactive bladder, Incontinence

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 1
    Interventional Study Model
    Crossover Assignment
    Masking
    Participant
    Allocation
    Randomized
    Enrollment
    24 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Formulation 1 solabegron
    Arm Type
    Experimental
    Arm Description
    Subjects will receive formulation 1 solabegron doses in a single-blind, randomized, cross-over fashion in Periods 1 to 3.
    Arm Title
    Formulation 2 solabegron
    Arm Type
    Experimental
    Arm Description
    Subjects will receive formulation 2 in a single-blind, randomized, cross-over fashion in Periods 1 to 3.
    Intervention Type
    Drug
    Intervention Name(s)
    Formulation 1 solabegron
    Intervention Type
    Drug
    Intervention Name(s)
    Formulation 2 solabegron
    Primary Outcome Measure Information:
    Title
    Maximum observed plasma drug concentration (Cmax)
    Time Frame
    24 hours

    10. Eligibility

    Sex
    Male
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    65 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Body weight greater than or equal to 50 kg, inclusive, and body mass index (BMI) 18.0 - 32.0 kg/m2, inclusive In good general health as determined by a thorough medical history and physical examination, ECG, vital signs, and clinical laboratory evaluation. Results of clinical laboratory tests must be without clinically significant abnormalities, including hematology, clinical chemistry and urinalysis. Adequate venous access to allow for repeated blood sampling Ability to understand and comply with the study requirements Provide written informed consent prior to any study procedure being performed (all subjects should be able to understand the informed consent form and any other documents that subjects are required to read). Exclusion Criteria: Any clinically relevant abnormality identified on the screening physical examination, clinical laboratory tests, 12-lead ECG, or any other medical condition or circumstance which would make the subject unsuitable for participation in the study based on the Investigator's assessment Resting heart rate greater than or equal to 100 beats per minute (BPM) after 5 minutes rest (as above) at the screening visit QTcF interval (Fredericia's correction factor) greater than 450 msec (males subjects) at screening History of drug or other allergy, which, in the opinion of the Investigator, contraindicates their participation History of smoking, including e-cigarettes, within 3 months of the study and/or a positive urine cotinine at screening Regular alcohol consumption averaging ≥ 14 drinks/week for men (1 drink = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of the first dose of study medication. Positive urine drug or alcohol test at screening Any other condition and/or situation that causes the Investigator to deem a subject unsuitable for the study (e.g., due to expected study medication non-compliance, inability to medically tolerate the study procedures, or a subject's unwillingness to comply with study-related procedures)
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Eliot Ohlstein, PhD
    Organizational Affiliation
    Velicept Therapeutics, Inc.
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Evaluate the Safety, Tolerability and PK of Different Formulations of Orally Administered Solabegron in Healthy Male Subjects

    We'll reach out to this number within 24 hrs